Research and Development Expenses: $39.4 million for the fiscal year ended March 31, 2025, up from $20 million the previous year. General and Administrative Expenses: $17.1 million for the fiscal year ended March 31, 2025, compared to $14.1 million the previous year. Net Loss: $51.4 million for the fiscal year ended March 31, 2025, compared
Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024. Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023. General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million
Research and Development Expenses (Q4 2024): $6 million, up from $4 million in Q4 2023. Research and Development Expenses (Full-Year 2024): $19.4 million, up from $16.5 million in 2023. Net Loss (Q4 2024): $12.1 million, compared to $6.7 million in Q4 2023. Net Loss (Full-Year 2024): $62.3 million, compared to $27.0 million in 2023. Stock
This is a scene from the Hallyu (Korean Wave) convention KCON LA in Los Angeles that ran from July 26-28, 2024. (CJ ENM) By Gil Kyuyoung The country’s copyright trade last year posted a surplus thanks to the popularity of Hallyu (Korean Wave) content. The Ministry of Culture, Sports and Tourism on March 19 said
Total Revenue: $150 million for the year ended December 31, 2024, up from $58.7 million in 2023. Revenue from Collaborative and Other Agreements: $118.9 million. MARGENZA Net Sales: $16.4 million. Contract Manufacturing Revenue: $13.1 million. Research and Development Expenses: $177.2 million, up from $166.6 million in 2023. Selling, General, and Administrative Expenses: $71 million, up
– Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $165 million upfront and eligible proceeds from Biogen collaboration anticipated to
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025
The advent of generative artificial intelligence has sent shock waves across industries, from the technical to the creative. AI systems that can generate viable computer code, write news stories and spin up professional-looking graphics have inspired countless headlines asking whether they will take away jobs in technology, journalism and design, among many other fields. And
GH Research PLC Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track